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Background and Significance
Cancer Prevalence & Treatment
• Cancer is the 2nd leading cause of death in the 
US causing 600,000 deaths annually
• While traditional treatment for cancer was 
infusion chemotherapy, there are more targeted 
oral therapies allowing for more precise 
treatment
• These newer oral oncology treatments must be 
secured from specialty pharmacies
Specialty Pharmacies
• Specialty medications are the fastest growing 
segment of the pharmaceutical industry and have 
dominated drug development for the past decade
• Specialty pharmacies typically dispense 
medications that are expensive, may require 
specific handling and preparation and are for 
complex disease states such as cancer
Objective
• Seek to better understand how the shift to 
specialty pharmacies has impacted patient care 
by  identifying challenges in securing medication 
and explore how the process can potentially be 
improved
Key Interview Responses Discussion
• The interviews revealed challenges obtaining oral 
oncology medications like those identified in the 
Peer Reviewed Literature
• Gap identified – there was no training or manual 
on the process – this became the deliverable
Conclusions
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Barriers identified in Peer 
Reviewed Literature
Process Barriers Included
• Insurance mandate to a particular specialty 
pharmacy
• Specialty Pharmacy’s lack of access to medication
• Insurance processing requirements such as PAs
• High out-of-pocket costs
Methodology
• Conducted literature review
• Selected oncology practice and met with nurse 
manager
• Drafted questions and conducted interviews
• Reviewed interview results
• Based on results identified process gap
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“It used to be that any one of the nurses in the practice 
could be asked to send in a prescription. About two 
years ago I [Nurse Manager] took over the responsibility 
for obtaining oral oncology medications.”
“If we are not going to dispense, many times due to the 
patient’s insurance, I will then either fax or escribe the 
prescription that will be filling.” 
“There can be a delay because a PA is required.”
“There is no real training for a new nurse. It would be 
learning as you go.”
“There is no guidebook or manual – new nurse would learn 
by asking the nurse manager or other nurses.”
“Getting funding for copays can delay the process.”
Limitations
• Small sample size
• Not an academic medical center clinic
• There are many challenges in securing oral 
oncology medications for patients
• It would be helpful for nurses to have a manual 
in order to provide a systematic approach –
this was developed
“There can be a delay because the pharmacy is unable 
to reach the patient to set up shipment.”
Interview Topics
• Nurses’ experience level
• Percent of patients on oral oncology medications
• Process for securing oral oncology medications
• Involvement in the process
• Challenges with the process
• Causes of delay in medication getting to patient
• What would make the process easier
“More than 60% of our patients are on oral oncology 
medications.”
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